Clinical Trials
166
Active:18
Completed:83
Trial Phases
4 Phases
Phase 1:105
Phase 2:27
Phase 3:31
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (164 trials with phase data)• Click on a phase to view related trials
Phase 1
105 (64.0%)Phase 3
31 (18.9%)Phase 2
27 (16.5%)Not Applicable
1 (0.6%)A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT07066098
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT07008287
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT07000955
- Locations
- 🇨🇳
The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06974812
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06947408
- Locations
- 🇨🇳
China-japan Friendship Hosipital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 33
- Next
News
No news found